The progress made in knowledge of the causes of diseases, the prediction of the course of chronic pathologies and of the therapeutic response are the foundation for continuing improvement of European people’s health and for providing personalised care appropriate for the needs and expectations of each individual. Current biomedical research requires new resources which include the use and handling of big data obtained from biological samples. The Biobank provides unique solutions for researching and documenting inter-individual diversity.
The CIBEREHD has created a platform which collects, stores and distributes biological samples connected with digestive diseases, which is supported by IDIBAPS Biobank infrastructure. This system incorporates an adaptive data model, and has developed processes for proper treatment of intellectual property, strategic aspects, services and maintenance.
The main objectives of the platform are:
To attain these objectives the platform has the following equipment:
CIBEREHD researchers currently use this platform in studies on genetic determinants and predictors in liver and digestive diseases, including inflammatory bowel disease, colorectal cancer, cholestatic diseases, vascular liver diseases (Budd-Chiari syndrome, portal vein thrombosis, idiopathic portal vein hypertension). Apart from these studies got under way by researchers, the samples of the CIBEREHD-IDIBAPS Biobank have been used in cooperation with the pharmaceutical industry, specifically in two studies which evaluate diagnostic tools for colorectal cancer.